Chester County News and Community Website
RADNOR, PA — Mineralys Therapeutics Inc. (Nasdaq: MLYS) granted stock options and restricted stock units covering a combined 52,080 shares to two newly hired non-executive employees as employment inducements under …
Mineralys Grants Equity Awards to Two New Employees Read More RADNOR, PA — Mineralys Therapeutics Inc. (Nasdaq: MLYS) will present to investors Sept. 9 at the Wells Fargo 21st Annual Healthcare Conference in Boston as the clinical-stage biotechnology company advances …
Mineralys Sets Investor Update as Lorundrostat Advances Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) granted equity awards covering 237,400 shares to newly appointed Chief Medical Officer Dr. Terry Ferguson on Aug. 10 as part of an …
Mineralys Grants Equity Awards to New Medical Chief Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) ended the second quarter with $661.4 million in cash, cash equivalents and investments after raising equity and debt capital and spending $200 …
Mineralys Builds $661 Million War Chest Ahead of FDA Decision Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) will report second-quarter 2026 financial results after U.S. markets close Tuesday, Aug. 11, as the biopharmaceutical company continues development of its lead …
Mineralys Sets Aug. 11 Earnings Update as Drug Work Advances Read More RADNOR, PA — Mineralys Therapeutics Inc. granted stock options and restricted stock units covering a combined 74,900 shares to two newly hired non-executive employees, using equity incentives to support recruitment …
Mineralys Grants Equity Awards to Two New Employees Read More RADNOR, PA — Mineralys Therapeutics (Nasdaq: MLYS) will present new clinical data on its investigational hypertension treatment lorundrostat at ENDO 2026, as the company advances the drug through late-stage development …
Mineralys Data Presentation Highlights Heart Failure Biomarkers Ahead of FDA Review Read More RADNOR, PA — Mineralys Therapeutics (NASDAQ: MLYS) has agreed to eliminate future royalty obligations tied to its lead drug candidate lorundrostat while securing access to up to $500 million in …
Mineralys Restructures Drug Economics With $500 Million Financing Read More RADNOR, PA — Mineralys Therapeutics (Nasdaq: MLYS) reported new Phase 3 data suggesting its experimental hypertension treatment lorundrostat may provide benefits for patients with chronic kidney disease, a finding that …
Mineralys Reports Kidney Disease Data Ahead of FDA Decision Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) received U.S. Food and Drug Administration acceptance for its application seeking approval of lorundrostat for uncontrolled or resistant hypertension, moving the company …
Mineralys Advances Hypertension Drug Toward FDA Decision Read More